#United States #Washington, D.C. #Public Health #PMI U.S. #smoking

PMI U.S. Calls for Action Against Smoking

Philip Morris International's U.S. division, PMI U.S., has issued a new white paper, titled The Forgotten Smoker: Modern Solutions to America's Oldest Public Health Challenge, shedding light on the ongoing smoking issue in America. Contrary to popular belief, the findings reveal that America has not successfully tackled smoking; rather, the problem persists and is compounded by stigma and misinformation.

Key Survey Findings

The national survey conducted by Povaddo among 2000 American adults aged 21 and over between February 27 and March 10, 2026, indicated that 79% of respondents believe more action is needed to combat smoking-related harm. The paper reveals numerous misconceptions, discovering that:

• - 52% of participants incorrectly think nicotine directly causes cancer.
• - 73% mistakenly believe all tobacco products bear equal risk to health.
• - 81% feel it is crucial for public health agencies like the FDA to disseminate scientifically supported information on tobacco products.
• - 63% agree on the need for FDA reforms to align with the emergence of newer smoke-free products.

Addressing the Stigma

PMI U.S. emphasizes the need to stop regarding smoking as a moral failing. Stacey Kennedy, CEO of PMI U.S., mentioned that many smokers feel judged and marginalized, and thus, strategic investments should focus on understanding and supporting 'forgotten smokers,' who have often been neglected by conventional anti-smoking campaigns.

Practical Recommendations

The white paper outlines a series of evidence-based recommendations aimed at reducing smoking-related harm, which include:
1. Engaging with Adult Smokers: 52% of smokers feel discriminated against. It's crucial for policies to treat smoking as a public health issue rather than a personal failing, ensuring that tailored support is available.
2. Education on Harm Reduction: There is a critical need for enhanced public and medical understanding of the relative risks associated with various tobacco products, especially clarification about tobacco harm reduction.
3. Access to Smoke-Free Alternatives: Although progress has been made, a backlog exists for FDA approvals of smoke-free alternatives. Long-term smokers deserve access to these scientifically backed options.
4. Combating Misinformation: A clear communication strategy from the FDA about the risks associated with tobacco products is essential, guiding smokers toward healthier, FDA-authorized options.
5. Implementing Risk-Based Taxation: The current tobacco tax structure disproportionately affects lower-income smokers. A more equitable tax policy should discourage high-risk products while promoting lower-risk alternatives.

Conclusion

Keagan Lenihan, Chief External Affairs Officer at PMI U.S., stressed the urgency in addressing the smoking epidemic, linking it directly to preventable death rates in the U.S. He emphasized the importance of the FDA’s role in authorizing better alternatives to cigarettes and enhancing public education regarding tobacco harm reduction.

In summary, the findings and recommendations outlined in PMI U.S.'s white paper serve as a clarion call to reconsider smoking's role in public health strategy, updating approaches and addressing the needs of countless Americans still deeply affected by smoking today.

For further insights, read the full white paper here.